AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells

Not Applicable

Completed

• Conditions: Acute Myeloid Leukemia

• Registration Number: NCT04169022
• Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Brief Summary

AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality. Despite progress in the treatment of leukemic malignancies, especially the emergence of targeted- and immuno-therapies arising from biological genomic knowledge, there remains a need to provide additional strategies for refractory/relapsing (R/R) patients

Aim of this study is to collect biological samples of AML patients in order to validate our Chimeric Antigen Receptor T-cells immunotherapy approach

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-05-16
• Study Start: 2019-07-10
• Study First Submitted QC: 2019-11-18
• Study First Posted: 2019-11-19
• Primary Completion: 2023-10-02
• Study Completion: 2023-10-02
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-08
• Last Update Posted: 2024-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

• AML patients adults and pediatrics

Exclusion Criteria

• AML3

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
IL1RAP protein expression	2 years	Cytometry analysis

Trial Locations

Locations (1)

CHU Besançon; 🇫🇷 Besançon, France